NY-ESO-1 peptide–major histocompatibility complex (MHC) complex (NY-ESO-1 peptide–MHC complex)

The **NY-ESO-1 peptide–major histocompatibility complex (MHC) complex** is a molecular assembly in which short peptides derived from the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) cancer/testis antigen are presented on the extracellular surface of cells by MHC class I (e.g., HLA-A*02:01) or class II molecules[2][3][4][5][7]. NY-ESO-1 peptides, such as the highly immunogenic 157–165 epitope (SLLMWITQC), are recognized by cytotoxic T lymphocytes (CTLs) when displayed by specific MHC alleles, making this complex a prominent target for cancer immunotherapy[2][3][6]. The complex plays a central role in the immune response against tumors that aberrantly express NY-ESO-1, stimulating both humoral and cellular immunity[3][6]. Multiple therapeutic modalities—including peptide vaccines, adoptive TCR-engineered T cells, and bispecific antibodies—have been developed to leverage this complex in the treatment of various malignancies, particularly in cancers expressing NY-ESO-1 and the corresponding MHC alleles[1][3][5]. The presence of the NY-ESO-1 peptide–MHC complex on tumor cells serves as a key biomarker for patient selection and as a stimulus for targeted immune responses, though challenges remain in preventing immune escape and minimizing off-tumor toxicity[6][1][3].

Other names

NY-ESO-1 (157-165) peptide–MHC complexNY-ESO-1/HLA-A*02:01 complexNY-ESO-1–pMHCSLLMWITQC/HLA-A2 complexNew York esophageal squamous cell carcinoma 1 peptide–MHC complex

Generation of cytotoxic CD8+ T lymphocyte responses upon presentation of NY-ESO-1 peptide by MHC I to TCRs on immune effector cells; Adoptive transfer of NY-ESO-1–specific TCR-transduced T cells that recognize peptide–MHC complex on tumor cells; Bispecific antibody-mediated recruitment of T cells to tumor cells displaying the peptide–MHC complex; Vaccine-induced activation of NY-ESO-1–specific immune responses